MNLO Menlo Therapeutics Phase2 Serlopitant

When:
March 2, 2019 all-day
2019-03-02T00:00:00-05:00
2019-03-03T00:00:00-05:00

MNLO Menlo Therapeutics Announces Late-Breaking Oral Presentation at the American Academy of Dermatology Annual Meeting for Serlopitant,
Pruritus associated with psoriasis.

Phase 2 data released December 10, 2018 – primary endpoint met. $MNLO Presentation of data March 2, 2019 1pm at American Academy of Dermatology Annual Meeting. Phase 3 planned for 2019.

$MNLO has approximately 77.80% Institutional Ownership and 19.12% Insider Ownership, with a rather low float of about 18M outstanding shares.

Menlo Therapeutics Announces Late-Breaking Oral Presentation at the American Academy of Dermatology Annual Meeting

Leave a Reply